Navigation Links
Morphotek Enters Into Agreements With Fox Chase Cancer Center to Acquire Clinical Samples for the Development and Validation of Companion Diagnostic Kits
Date:1/10/2012

s in 1997. Since that time, Eisai has rapidly grown to become a fully integrated pharmaceutical business.  Eisai's areas of commercial focus include neurology, gastrointestinal disorders and oncology/critical care.  The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. 

Eisai has a global product creation organization that includes U.S.-based R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania as well as manufacturing facilities in Maryland and North Carolina.  The company's areas of R&D focus include neuroscience; oncology; vascular, inflammatory and immunological reaction; and antibody-based programs.  For more information about Eisai, please visit www.eisai.com/US.

 Contact: Media InquiriesInvestor Inquiries 

Terry Cushmore

Rod Dausch 

Morphotek, Inc.

Morphotek, Inc. 

610-423-6197

610-423-6111 

tcushmore@morphotek.com

Dausch@morphotek.com  

 

  

Lynn Kenney

Alex Scott  

Eisai Inc.

Eisai Inc. 

201-746-2294

201-746-2177 

lynn_kenny@eisai.com

alex_scott@eisai.com


'/>"/>
SOURCE Morphotek, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Morphotek®, Inc. Announces Initiation of Farletuzumab Phase II Study in First-Line Treatment of Non-Small Cell Lung Cancer
2. Morphotek, Inc. Announces That Two Investigational Drugs Have Received Orphan Drug Designations
3. Morphotek®, Inc. Announces Acquisition of Tumor Targeting Assets From Transmolecular, Inc.
4. MacuCLEAR, Inc. Raises More Than $1M in Financing and Enters into Strategic Pacific Rim Partnership
5. Medical Centers Worldwide Adopt Both Accurays CyberKnife and TomoTherapy Systems
6. Dehaier Medical Enters European Homecare Medical Product Market
7. Molecular Imaging, Inc. Enters Relationship with Dana-Farber Cancer Institute to Expand Luciferase-reporter Cancer Cell Lines for Preclinical in vivo Imaging
8. Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Megapharm Ltd. for Commercialization of Fanapt™ in Israel
9. HeartSine® Technologies Now Exclusive Provider of Lifesaving AEDs to Golden LivingCenters
10. CIVCO Enters CT Needle Guidance Market with RAD-GUIDE™ Launch
11. Innocoll Enters Partnership with Merus Labs in Canada for the Distribution of CollaGUARD
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire-iReach/ -- Market Research ... Industry, 2009-2019 is a professional and in-depth market ... Scanner industry . The report firstly reviews the ... classification, application and manufacturing technology. The report then ... Crystallography Scanner listing their product specification, capacity, Production ...
(Date:8/29/2014)... 2014 The clinical and medical insights provided ... between a product,s success or failure. Despite this, many ... targets – and then to coordinate activities and outreach ... upon which successful KOL engagement rests. ... internal inconsistencies in their KOL management systems and are ...
(Date:8/29/2014)... /PRNewswire-iReach/ -- SAM Medical Products Implements Voluntary Recall ... Junctional Tourniquet.  Photo - ... announced today that it has begun notifying customers ... issue with a clip used to secure the ... the SAM Junctional Tourniquet (SJT).  The company discovered ...
Breaking Medicine Technology:X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 2X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 3X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 4X-Ray Crystallography Scanner Industry For Global and Chinese Market Forecast to 2019 5Implementing a Strategic Thought Leader Management & Engagement System 2SAM Medical Products Implements Voluntary Recall of its Accessory (Axilla) Strap for the SAM Junctional Tourniquet. 2
... to Phase 3; Eligible for Accelerated Approval; ... Global Regulatory Plan Expected by Year End, CRANBURY, ... a biopharmaceutical company developing small molecule,orally-administered pharmacological chaperones for ... has successfully completed an End,of Phase 2 meeting for ...
... Rare Genetic Disorder in,Children--, PHILADELPHIA, July 31 ... levels of blood sugar in animals genetically,engineered to ... in humans, it could become an innovative medicine ... devastating genetic,disease in which insulin levels become dangerously ...
Cached Medicine Technology:Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease 2Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease 3Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease 4Treatment Corrects Severe Insulin Imbalance in Animal Studies 2Treatment Corrects Severe Insulin Imbalance in Animal Studies 3
(Date:9/2/2014)... 02, 2014 The Quantum Group, ... Quantum Innovations, Inc . (QI), it has submitted ... MU2 Certification with a private IT security laboratory approved ... The platform has Meaningful Use 1 certification status (see ... approved and 15 pending patents. The accrediting organization has ...
(Date:9/2/2014)... public support for marijuana legalization in the U.S. has ... than other substances, such as alcohol. In January, President ... marijuana is more dangerous than alcohol. Despite the recent ... as compared to alcohol use are not well understood. ... Outcomes Associated with Drug Use among US High School ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 At the ... Prosupps will be an exhibitor at the Las ... Rd, Las Vegas, NV 89109 Booth #374 Sept 19th ... to encourage healthy living through exercise, diet and supplementation. ... vision, and provide the tools for all Prosupps customers ...
(Date:9/2/2014)... Smile Squared, a well-known Buy One, Give ... a US-made toothbrush. For every toothbrush purchased, Smile Squared ... Squared was created by my wife and me after ... Cope, President of Smile Squared. “There, we saw children ... many of the same children didn't own a toothbrush. ...
(Date:9/2/2014)... Tuesday 2 September 2014: Digoxin may increase the ... by approximately 20%, according to results from the ROCKET ... Manesh Patel, director of interventional cardiology and catheterisation labs ... US. The findings suggest that caution may be needed ... studies are needed to confirm the observations. , Dr ...
Breaking Medicine News(10 mins):Health News:Grace Century’s EHR Project, The Quantum Group, Inc., Announces Submission for MU2 Certification 2Health News:Grace Century’s EHR Project, The Quantum Group, Inc., Announces Submission for MU2 Certification 3Health News:Grace Century’s EHR Project, The Quantum Group, Inc., Announces Submission for MU2 Certification 4Health News:Grace Century’s EHR Project, The Quantum Group, Inc., Announces Submission for MU2 Certification 5Health News:NYU study compares consequences of teen alcohol and marijuana use 2Health News:NYU study compares consequences of teen alcohol and marijuana use 3Health News:Prosupps, One of the Fastest Growing Supplement Companies, Celebrates a Success Milestone with Exhibiting at the 50th Annual 2014 Mr. Olympia’s Fitness & Performance Expo 2Health News:Smile Squared's Colorful Buy One, Give One Toothbrush Now Available in Schnucks Stores 2Health News:ROCKET AF trial suggests that digoxin increases risk of death in AF patients 2
... MISSISSAUGA, ON, May 13 /PRNewswire-FirstCall/ - Cipher Pharmaceuticals,Inc. ... Drug Application (NDA),has been submitted to the U.S. ... extended-release formulation of tramadol. In May 2007,the Company ... to its,NDA for CIP-TRAMADOL ER., Cipher,s revised ...
... May 13 Lumenis Inc., a global,developer, ... radiofrequency,devices for surgical, aesthetic, and ophthalmic applications, ... Enucleation of the Prostate (HoLEP),preceptor program that ... interested in learning and performing HoLEP. The ...
... Project proceeds despite non-compliance with California Environmental ... Quality ... Center (PHCMC) today went ahead with the planned expansion of its,Holy ... has upheld charges that the approval process was significantly flawed.,The groundbreaking ...
... 12 /PRNewswire-FirstCall/ - Med-Emerg International Inc.,(OTCBB - MDER), ... three months ended March 31, 2008 were $5.5 ... in 2007 (all amounts are $US unless,otherwise stated). ... interest and taxes (EBITDA) improved to $179K,from a ...
... TSX:,WHT) World Heart Corporation ("WorldHeart" or the "Corporation") ... Bulletin today advising it,is reviewing the eligibility for ... of WorldHeart under sections 709 and 710(a) of ... Company,s financial condition and,operating results, more specifically whether ...
... Institute (KGI),today announced that the May 17, 2008, commencement ... Applied Life Sciences student, Eric,Tan, and the unveiling of ... and proud of Eric,s achievement in becoming the,first graduate ... KGI,s senior,vice president for academic affairs, dean of faculty ...
Cached Medicine News:Health News:Cipher provides regulatory update for CIP-TRAMADOL ER 2Health News:Cipher provides regulatory update for CIP-TRAMADOL ER 3Health News:Lumenis Launches HoLEP Preceptor Program at American Urology Association 2008 Annual Meeting 2Health News:Lumenis Launches HoLEP Preceptor Program at American Urology Association 2008 Annual Meeting 3Health News:Providence Holy Cross Medical Center Ignores Community, Environmental Concerns With Planned Expansion of Mission Hills Facility 2Health News:Med-Emerg International Inc. reports improved income from continuing operations 2Health News:Med-Emerg International Inc. reports improved income from continuing operations 3Health News:WorldHeart Notified of TSX Delisting Review 2Health News:KGI 2008 Commencement Features First PhD Graduate, Biotech Painting 2
... The ImmunoWELL VZV IgG ... for the qualitative detection of ... (VZV). Test results are used ... status or infection. Immune status ...
... Test is an enzyme immunoassay (EIA) test ... human thyroglobulin and human thyroid peroxidase (microsome) ... is used as an aid in the ... disorders are characterized by detection of anti-thyroid ...
... ImmunoDOT Autoimmunity Screening Panel 1 is ... screening and detection of autoantibodies against ... SS-A/SS-B, RNP/Sm) in serum, and is ... diagnosis of systemic lupus erythematosus (SLE), ...
... Antibody (IgG) Test is an ... quantitative detection of antibodies to ... is used as an aid ... thrombosis in individuals with systemic ...
Medicine Products: